![Spatial analysis and temporal trends of porcine reproductive ......pneumonia, Porcine pleuropneumonia, Swine dysentery, Atrophic rhinitis, PRRS, mange and lice [17]. This program is](https://static.fdocuments.in/doc/165x107/60862d748ad3ad7d051ffbbe/spatial-analysis-and-temporal-trends-of-porcine-reproductive-pneumonia.jpg)
Dr. PH Rathkjen - Porcine Reproductive & Respiratory Syndrome (PRRS) around the World – What’s...
45
PH Rathkjen Sr. Global Technical manager PRRS Boehringer Ingelheim Animal Health GmbH – What’s new regarding Global cross-protection against PRRS? PRRS from around the world
Transcript of Dr. PH Rathkjen - Porcine Reproductive & Respiratory Syndrome (PRRS) around the World – What’s...
PH RathkjenSr. Global Technical manager PRRS
Boehringer Ingelheim Animal Health GmbH
– What’s new regarding Global cross-protection against PRRS?
PRRS from around the world
From 22 years experienceof heterologous protection against the economically most important disease across the globe in19 countriesin Asia, Europe and North America
Real world situation· Low Immunity level + High Pathogen challenge
The solution is bigger than the bottle· Maximize immunity & Minimize exposure
What isimportant tocontrolPRRSV?
People are the most important Gilts
replacement proceduresare the most
important
Location is the most
important What about
pig Flow?
You also need
a good Immunity
Do we need to take
PRRSV diversityInto
Consideration?
HeterologousProtection!
No matter the virus.
That is whatYou
Need!
North America: PRRSV type IIsome type I
Most South America:
FreeAustralia:Free
Eastern Europe: PRRSV type I (2,3)
Western Europe:PRRSV type I (1) some type II
Asia:PRRSV type II (HP) some type I
Our basic understanding of PRRSV global distribution
Results: Differences between vaccinated and challenge control animals were statistically significant (P<0.05) in all studies.
Conclusion:
· Under the conditions of these studies, Ingelvac PRRS® MLV significantly reduced lung lesions in multiple challenge models which used genetically diverse heterologous PRRSV isolates.
Homology (%)
94%100%90%89%90%87%87%89%89%87%87%88%86%87%
NorthAmerica
EuropeAsia
Heterologous protection fromA 22 year old PRRS MLV vaccinedocumented globally
ChinaGuo, IPVS 2008
Fang, APVS 2009Liu, IPVS 2010Ao, IPVS 2010Lin, IPVS 2010
Zhu, IPVS 2011Yao, APVS 2011Fang, IPVS 2012Peng, IPVS 2012
Wei, Vaccine 2013
Lager, Vaccine 2014
Xu IPVS 2016Tian IPVS 2016
Huang IPVS 2016
KoreaLee, APVS 2015
Kang, APVS 2015Seo, APVS 2015
Jung, Vet, Micr. 2016Lyoo, Virology 2016
Bae, IPVS 2016Jongyoung, IPVS 2016
Lee, IPVS 2016
VietnamLager, Vaccine 2014
ThailandMeedacha, APVS 2009Kongtes, APVS 2011
Krualoy, IPVS 2012Poommarin, IPVS 2016Duanghwae, IPVS 2016Duanghwae , IPVS 2016
PhilipinesManabat, IPVS 2010
DenmarkNielsen, Vet Micr 1997
Kvisgaard PhD thesis 2013Kristensen, SEGES 2016
GermanyPesch, IPVS 2000
Nickoll, IPVS 2002Medveczkyet, Tier. Um. 2002
Kovacs, 2003Heller, IPVS 2004
Schröder , IPVS 2004Schoun , 2007
HungaryBelgium
USA Osorio, Leman 1998Halbur, Leman 1999
Roof, IPVS 2000Opriessnig, JSHAP 2005
Cano , Vaccine 2007Zuckerman, Vet Micr 2007
Charerntantanakol, Vet Imm & Imm 2006Waddell, AASV 2008Jordan, Leman 2009Reicks, Leman 2010
Miller, AASV 2011Garbes,Leman 2011
Linhares, Vaccine 2011Garbes, AASV 2012
Li, BioMed Res. 2014Dee, AASV 2014
Patterson, Leman 2013 and AASV 2014Patterson, Leman 2016
Haiwick, AASV 2016Haiwick, AASV 2016
Ouyang, Vet Res 2016
MexicoAngulo, Leman 2007
Diaz, AASV 2011Diaz IPVS 2012
Centeno, IPVS 2016
CanadaDesrosiers, APVS 2007
JapanMuehlenthaler, 2012
Kitano, APVS 2015
Worldwide documentation
Japanese isolate bs403929 (internal RD data 2012)
EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL
USA SDSU-73 2016
USA, 1-7-4- 2016
China HP-PRRS 2013
Korean PRRS isolates 2015
· Japanese isolate bs403929
EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL
internal RD data 2012
28 days
VaccinationIngelvac
PRRS® MLV
3 WOA 2 X 20PRRS neg.
· Japanese isolate bs403929
· EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL
· internal RD data 2012
BloodWeight
BloodWeight
BloodWeightBlood Blood
14 days
Blood
Design Parameters Results Moving graphs
Design Parameters Results Moving graphs
Fever (6,7 days vs 3,9 days)
Serum viremia
BAL d 42
Diluent MLV0
0.1
0.2
0.3
0.4
0.5
0.6
0.56 0.54
0.25
0.44
ADWG by group and study period
Vaccination periodChallenge period
ADW
G kg
P=0,0040
Diluent MLV0
5
10
15
20
Percent pneumonia
Average lung lesion
Treatment group
Perc
ent c
onso
lidati
on
P=0,0045
EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL. internal BI R+D data 2012
EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL. internal BI R+D data 2012
Design Parameters Results Moving graphs
EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL. internal BI R+D data 2012
Design Parameters Results Moving graphs
28 days
28 doa 2 X 22PRRS neg.
Blood Blood BloodBlood Blood
21 days
BloodBlood Blood
0 7 14 21 42353228
VaccinationIngelvac
PRRS® MLV
Design Parameters Results Moving graphs
Survival curve
0102030405060708090
100
V/C Non-V/C Strict controls
Surv
ival
rate
in %
Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSVJX143
Design Parameters Results Moving graphs
Percent PCR positive & body temperature
chall
enge d3
0d3
1d3
2 d33
d34
d35
d36
d37
d38
d39
d40
d41
d42
d43
d44
d45
d46
d47
d48
Necrop
sy38.5
39
39.5
40
40.5
41
41.5
0
10
20
30
40
50
60
70
80
90
100
V/C group -PCR NV/C group - PCR V/C group - temp NV/C group -temp
Bod
y te
mpe
ratu
re in
°C
% P
CR
pos
itive
s
Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSVJX143
Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSVJX143
Design Parameters Results Moving graphs
Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSVJX143
Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSVJX143
Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSVJX143
Design Parameters Results Moving graphs
VaccinationIngelvac
PRRS® MLV 35 days
21 doa4 X 301 x 10PRRS neg. Blood Blood BloodBlood Blood
21 days
BloodBlood Blood
d0 7 14 21 45423835
Blood
49
Daily monitoring clinic, temperature d0 – d49
Strict controls 2 NV --> chall. Diff.
strains (lineage 1 or 5) 2 Vax--> chall. Diff.
strains (lineage 1 or 5)
Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against two recent type 2 PRRS virus isolates in South Korea,
Design Parameters Results Moving graphs
Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against two recent type 2 PRRS virus isolates in South Korea,
Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against two recent type 2 PRRS virus isolates in South Korea,
Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against two recent type 2 PRRS virus isolates in South Korea,
Patterson 2016
Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge, Patterson et al, Leman 2016
Design Parameters Results Moving graphs
28 days
159 PRRSV Neg
28 DOA
BloodWeight
ClinTemp
BloodWeightTempClin
NecropsyWeight Temp
Serum Clin
BloodTemp
BloodTemp
14 days
BloodTemp Blood, Temp
0 7 14 21 42352928 31
IngelvacPRRS® MLV
Group n Treatment
1 45 Ingelvac PRRS® MLV
2 45 Fostera® PRRS
3 65 Placebo
Design Parameters Results Moving graphs
Day 42 Percent Lung Lesions (Median)
asignificantly different from the placebo at P≤0.05
Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,
Design Parameters Results Moving graphs
Post-challenge ADWG
Group Treatment ADWG in lbs.
1 Ingelvac PRRS® MLV 0.61a
2 Fostera® PRRS 0.49a*
3 Placebo 0.24b
asignificantly different from the placebo at P≤0.05*different from Ingelvac PRRS® MLV at P≤0.1
Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,
Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,
Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,
Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,
Design Parameters Results Moving graphs
Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,
Design Parameters Results Moving graphs
28 days
90 PRRSV Neg
21 DOA
VirusWeight
ClinTemp
VirusWeightTempClin
NecropsyWeight Temp
Serum Clin
VirusTemp
VirusTemp
70 days
VirusTemp Virus
0 7 14 21 38352928 31
IngelvacPRRS® MLV
42 70
Temp daily 14 days, then weekly
SDSU-73
Group VX Cont Chal log
1 10 10 4
2 10 10 3
3 10 10 2
4 10 10 1
5 10 no
Design Parameters Results Moving graphs
G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs
This study has relevance in the field as implementation of vaccine in a systematic and coordinated methodology in a “system-based” and “area/region-based” program can mitigate the consequences of PRRSV infection – subsequently improving health and performance – and may reduce the level of challenge virus within and between vaccinated populations over-time further limiting the consequences of infection in vaccinated populationsReid Philips, AASV 2016
Design Parameters Results Moving graphs
G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs
G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs
G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs
PRRS immunity across the world
Wei, Vaccine 2013
Jeung, Vet, Micr. 2016Patterson 2016
Muehlenthaler, 2012
Haiwick 2016
What’s new on immunological cross-protection
■ Genotype does not predict the level of protection■ Nothing new!
■ Geography does not predict the level of protection■ Nothing new!
■ Challenge dose plays an important role in the level of efficacy■ Reduction of wild type circulation is important
Reid Philips Enrique Mondaca Xavier de Paz Carlo Maala
Ryan Huang Oliver Duran Joe Victoria A. PattersonG. Haiwick
Thanks to
